Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. (Q42004227)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562384%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562384%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562384%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Athanasios Dimopoulos

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562384%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

P Richardson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562384%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

P Moreau

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562384%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

C Mitsiades

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562384%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

D Weber

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562384%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

J Houp

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562384%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

C Gause

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562384%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

S Vuocolo

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562384%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

J Eid

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562384%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

T Graef

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562384%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

K C Anderson

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562384%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

21 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562384%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562384%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562384%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

e182

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562384%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/bcj.2014.1

8 March 2020

exact match

0 references

cites work

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3944659

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3944659

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3944659

Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3944659

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3944659

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3944659

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3944659

Therapy of relapsed and refractory multiple myeloma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3944659

Treatment options for relapsed and refractory multiple myeloma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3944659

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3944659

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3944659

Vorinostat in solid and hematologic malignancies

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3944659

Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3944659

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3944659

Histone deacetylase inhibitors: molecular mechanisms of action

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3944659

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3944659

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3944659

Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3944659

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3944659

Management of relapsed and relapsed/refractory multiple myeloma

17 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24562384

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BCJ.2014.1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562384%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

8 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562384%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562384%20AND%20SRC:MED&resulttype=core&format=json